← All sarcoma trials
Opening soonPhase 2Ages 18 Years and up

Assessment of the Long-term Efficacy of Moderately Hypofractionated Neoadjuvant Radiotherapy Soft Tissue Sarcoma in the Limbs or Trunk Wall

Sponsor: Centre Oscar Lambret · NCT07507773 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Soft Tissue Sarcoma AdultSoft Tissue Sarcoma (Excluding GIST)Soft Tissue Sarcoma of the Trunk and ExtremitiesSoft Tissue Sarcoma of the Limb

What it tests

  • Moderately hypofractionated neoadjuvant radiotherapyradiation

Where it's running1 site

1 international site

  • Centre Oscar Lambret

    Lille, France 59000

    • Abel CORDOBA, MD(contact)+33(0)20295920[email protected]
    • Abel CORDOBA, MD(principal investigator)
    • Pauline LEMOINE-GOBERT, MD(sub investigator)
    • Isaure ROQUETTE, MD(sub investigator)
    • Mehrad JAFARI, MD(sub investigator)
    • Gauthier DECANTER, MD(sub investigator)
    • Antoine CAYEUX, MD(sub investigator)
    • Justine KHDOR, MD(sub investigator)
    • Thomas RYCKEWAERT, MD(sub investigator)
    • Loïc LEBELLEC, MD(sub investigator)
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Patient aged ≥ 18 years ;
* Localised sarcoma of a limb, the root of a limb, or the trunk wall ;
* Histologically confirmed diagnosis of soft tissue sarcoma regardless of the grade ;
* Diagnosis biopsy performed at Centre Oscar Lambret, with specimen available for translational research ;
* Indication of neoadjuvant radiotherapy according to the multidisciplinary consultation meeting ;
* Tumor considered operable with a curative intent and conservative intent according to the multidisciplinary consultation meeting ;
* Affiliation to the French National Social Security System ;
* Informed and signed consent

Exclusion Criteria:

* Metastatic disease (including local lymph node diffusion) ;
* Visceral or retroperitoneal sarcoma ;
* Tumor considered inoperable even after radiotherapy, according to the multidisciplinary consultation meeting ;
* Indication of neoadjuvant or adjuvant chemotherapy ;
* Ewing tumor of soft tissue, desmoid tumor, embryonal or alveolar rhabdomyosarcoma ;
* Pregnant or breastfeeding women ;
* Patients under protective measures ;
* Patient refusal.

Updated 2026-04-02 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.